Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis

BMC Gastroenterology

Shiying Xuan¹  Quanjiang Dong¹  Xiangjun Jiang¹  Yongning Xin¹  Zhonghua Lin¹  Wenwen Jin¹ 

[1]Qingdao City Key Laboratory of Digestive Diseases, Qingdao 266021, China

关键词: meta-analysis;    diagnostic accuracy;    liver fibrosis;    HBV;    APRI;   

Others  :  1113142
DOI  :  10.1186/1471-230X-12-14

 received in 2011-08-14, accepted in 2012-02-14,  发布年份 2012

【 摘 要 】

Background

The aspartate aminotransferase-to-platelet ratio index (APRI), a tool with limited expense and widespread availability, is a promising noninvasive alternative to liver biopsy for detecting hepatic fibrosis. The objective of this study was to systematically review the performance of the APRI in predicting significant fibrosis and cirrhosis in hepatitis B-related fibrosis.

Methods

Areas under summary receiver operating characteristic curves (AUROC), sensitivity and specificity were used to examine the accuracy of the APRI for the diagnosis of hepatitis B-related significant fibrosis and cirrhosis. Heterogeneity was explored using meta-regression.

Results

Nine studies were included in this meta-analysis (n = 1,798). Prevalence of significant fibrosis and cirrhosis were 53.1% and 13.5%, respectively. The summary AUCs of the APRI for significant fibrosis and cirrhosis were 0.79 and 0.75, respectively. For significant fibrosis, an APRI threshold of 0.5 was 84% sensitive and 41% specific. At the cutoff of 1.5, the summary sensitivity and specificity were 49% and 84%, respectively. For cirrhosis, an APRI threshold of 1.0-1.5 was 54% sensitive and 78% specific. At the cutoff of 2.0, the summary sensitivity and specificity were 28% and 87%, respectively. Meta-regression analysis indicated that the APRI accuracy for both significant fibrosis and cirrhosis was affected by histological classification systems, but not influenced by the interval between Biopsy & APRI or blind biopsy.

Conclusion

Our meta-analysis suggests that APRI show limited value in identifying hepatitis B-related significant fibrosis and cirrhosis.

【 授权许可】

   
2012 Jin et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Wright TL: Introduction to chronic hepatitis B infection. Am J Gastroenterol 2006, 101(Suppl 1):S1-6.
• [2]Friedman LS: Controversies in liver biopsy: who, where, when, how, why? Curr Gastroenterol Rep 2004, 6:30-36.
• [3]Bedossa P, Dargere D, Paradis V: Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-1457.
• [4]Douds AC, Joseph AE, Finlayson C, et al.: Is day case liver biopsy underutilised? Gut 1995, 37:574-575.
• [5]Piccinino F, Sagnelli E, Pasquale G, et al.: Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986, 2:165-173.
• [6]Wai CT, Greenson JK, Fontana RJ, et al.: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-526.
• [7]Whiting P, Rutjes AW, Reitsma JB, et al.: The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003, 3:25. BioMed Central Full Text
• [8]Whiting P, Rutjes AW, Dinnes J, et al.: Development and validation of methods for assessing the quality of diagnostic accuracy studies. Health Technol Assess 2004, 8:1-234. iii
• [9]Bedossa P, Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-293.
• [10]Batts KP, Ludwig J: Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995, 19:1409-1417.
• [11]Scheuer PJ: Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991, 13:372-374.
• [12]Ishak K, Baptista A, Bianchi L, et al.: Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22:696-699.
• [13]Schmid CH, Stark PC, Berlin JA, et al.: Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. J Clin Epidemiol 2004, 57:683-697.
• [14]Wai CT, Cheng CL, Wee A, et al.: Non-invasive models for predicting histology in patients with chronic hepatitis B. Liver Int 2006, 26:666-672.
• [15]Xu J, Shi J, Wang YP, et al.: Milder liver cirrhosis and loss of serum HBeAg do not imply lower risk for hepatocellular carcinoma development in HBV-related cirrhosis. Med Sci Monit 2009, 15:CR274-279.
• [16]Kim do Y, Kim SU, Ahn SH, et al.: Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B. Dig Dis Sci 2009, 54:1758-1763.
• [17]Tu XL, Xiao YQ, Chen F: A noninvasive model to predict histological liver cirrhosis in patients with chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2009, 17:28-32.
• [18]Zhang YX, Wu WJ, Zhang YZ, et al.: Noninvasive assessment of liver fibrosis with combined serum aminotransferase/platelet ratio index and hyaluronic acid in patients with chronic hepatitis B. World J Gastroenterol 2008, 14:7117-7121.
• [19]Pissaia A Jr, Borderie D, Bernard D, et al.: APRI and FIB-4 Scores Are Useful After Liver Transplantation Independently of Etiology. Transplant Proc 2009, 41:679-681.
• [20]Obara N, Ueno Y, Fukushima K, et al.: Transient elastography for measurement of liver stiffness measurement can detect early significant hepatic fibrosis in Japanese patients with viral and nonviral liver diseases. J Gastroenterol 2008, 43:720-728.
• [21]Wu SD, Wang JY, Li L: Staging of liver fibrosis in chronic hepatitis B patients with a composite predictive model: a comparative study. World J Gastroenterol 2010, 16:501-507.
• [22]Sebastiani G, Vario A, Guido M, et al.: Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2007, 13:525-531.
• [23]Chrysanthos NV, Papatheodoridis GV, Savvas S, et al.: Aspartate aminotransferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis. Eur J Gastroenterol Hepatol 2006, 18:389-396.
• [24]Shin WG, Park SH, Jang MK, et al.: Aspartate aminotransferase to platelet ratio index (APRI) can predict liver fibrosis in chronic hepatitis B. Dig Liver Dis 2008, 40:267-274.
• [25]Hongbo L, Xiaohui L, Hong K, et al.: Assessing routine and serum markers of liver fibrosis in CHB patients using parallel and serial interpretation. Clin Biochem 2007, 40:562-566.
• [26]Lin CS, Chang CS, Yang SS, et al.: Retrospective evaluation of serum markers APRI and AST/ALT for assessing liver fibrosis and cirrhosis in chronic hepatitis B and C patients with hepatocellular carcinoma. Intern Med 2008, 47:569-575.
• [27]Kim BK, Kim SA, Park YN, et al.: Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B. Liver Int 2007, 27:969-976.
• [28]Zheng RD ZK, Xian JC, Xu HT, Chen XX, Shen YL, Mao YM, Zeng MD, Lu LG: Assessment of noninvasive diagnostic models for predicting liver fibrosis in patients with chronic hepatitis B virus infection. Chin Hepatol 2008, 13:451-455.
• [29]Jiang ZS WX, Ke L, Tan C, Chen N, Li MJ: The diagnostic value of APRI and Forns index for liver fibrosis of chronic hepatitis B. Chin J Clini Hepatol 2008, 24:423-425.
• [30]Castera L, Vergniol J, Foucher J, et al.: Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343-350.
• [31]Carvalho-Filho RJ, Schiavon LL, Narciso-Schiavon JL, et al.: Optimized cutoffs improve performance of the aspartate aminotransferase to platelet ratio index for predicting significant liver fibrosis in human immunodeficiency virus/hepatitis C virus co-infection. Liver Int 2008, 28:486-493.
• [32]Sinn DH, Paik SW, Kang P, et al.: Disease progression and the risk factor analysis for chronic hepatitis C. Liver Int 2008, 28:1363-1369.
• [33]Toniutto P, Fabris C, Bitetto D, et al.: Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation. J Gastroenterol Hepatol 2007, 22:1904-1908.
• [34]Snyder N, Gajula L, Xiao SY, et al.: APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol 2006, 40:535-542.
• [35]Fabris C, Smirne C, Toniutto P, et al.: Assessment of liver fibrosis progression in patients with chronic hepatitis C and normal alanine aminotransferase values: the role of AST to the platelet ratio index. Clin Biochem 2006, 39:339-343.
• [36]Shaheen AA, Myers RP: Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007, 46:912-921.
• [37]Afdhal NH, Curry M: Technology evaluation: a critical step in the clinical utilization of novel diagnostic tests for liver fibrosis. J Hepatol 2007, 46:543-545.